Gastroduodenal “Dysbiosis”: a New Clinical Entity

AbstractPurpose of reviewLike the rest of the gastrointestinal tract, the small intestine is colonised by microbes, but how this “microbiome” affects the immune system and digestive functions has largely been overlooked, especially in the “omics” era. Here, we present recent findings that show that the diversity, density and interactions of these microbes in the small intestine can play an important role in the pathog enesis of a number of gastrointestinal and extraintestinal disorders.Recent findingsChanges in the small intestinal mucosa-associated microbiota (SI-MAM) have been shown to occur with inflammatory bowel diseases, functional gastrointestinal disorders, metabolic disorders such as obesity and type 2 diabetes. More recently, there is emerging evidence that small intestinal dysbiosis can be a driver for the progression of chronic liver disease. Initially believed that small intestinal dysbiosis (e.g. SIBO) is mainly due to alterations of luminal conditions (e.g. after surgical resections of the ileocecal valve), there is now enough evidence to conclude that small intestinal dysbiosis can occur without underlying structural abnormalities.SummaryAlterations of the SI-MAM appear to play a key role for the manifestation and progression of inflammatory and metabolic disorders.

Source: Current Treatment Options in Gastroenterology - November 12, 2018 Category: Gastroenterology Source Type: research